flipper44,
I followed the Vical Allovectin-7 saga fairly closely, near the end especially. Their Phase 2 data was not nearly as compelling as what is available now with DCVax-L from all sources. Sad to see that the CEO at Vical got a free pass for "his interpretation" of the facts to shareholders. I followed his comments very closely and he knew the enrollment numbers which was critical info for investors but did not release that to them. Some of the last remarks he made prior to announced failure would be described by most as upbeat and encouraging. The courts decided to let this slide in essence saying buyer beware. Those who really believe Linda would do the same thing because she could are probably long gone but if not AVII has warned them even though the obscurred comparison to NWBO numbers from data is faulty.
I did not invest in VICL because data was not strong enough and consensus from oncologist commentors was imminent failure. My confidence level based on my personal understanding of the science was also too low to even take a small position. I only chose to follow it because it was immunotherapy based.
VICL is a poor comparison for AVII to use but if the message to us all is "NWBO is not a slam dunk so check down on emotional investing and setting short term time lines" then I am in agreement with that.